Abstract:
We report a case of primary small cell carcinoma of the esophagus in a patient with achalasia in whom pro-gastrin-releasing peptide (ProGRP) and neuron-specific enolase (NSE) levels were measured. Although chemotherapy markedly reduced the size of the primary tumor and lymph node metastases, it had no effect on liver metastases. The tumor marker levels decreased after chemotherapy as the primary tumor and lymph node metastases decreased in size, and they increased as the liver metastases enlarged. However, there was a discrepancy between the levels of ProGRP and NSE during the patient's clinical course. We demonstrate the usfulness of measuring ProGRP and NSE levels to assess the effect of chemotherapy in patients with esophageal small cell carcinoma.
Similar content being viewed by others
Author information
Authors and Affiliations
Additional information
Received: April 30, 1998/Accepted: November 27, 1998
Rights and permissions
About this article
Cite this article
Suzuki, H., Takayanagi, S., Otake, T. et al. Primary small cell carcinoma of the esophagus with achalasia in a patient in whom pro-gastrin-releasing peptide and neuron-specific enolase levels reflected the clinical course during chemotherapy. J Gastroenterol 34, 378–382 (1999). https://doi.org/10.1007/s005350050278
Issue Date:
DOI: https://doi.org/10.1007/s005350050278